A phase 3, randomized, double-blind, multicenter study of talabostat and pemetrexed [Alimta; Eli Lilly] vs. pemetrexed and placebo in patients with advanced (stage IIIB/IV) non-small cell lung cancer (NSCLC) after failure of platinum-based chemotherapy

Trial Profile

A phase 3, randomized, double-blind, multicenter study of talabostat and pemetrexed [Alimta; Eli Lilly] vs. pemetrexed and placebo in patients with advanced (stage IIIB/IV) non-small cell lung cancer (NSCLC) after failure of platinum-based chemotherapy

Discontinued
Phase of Trial: Phase III

Latest Information Update: 07 Jun 2007

At a glance

  • Drugs Pemetrexed; Talabostat
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Point Therapeutics
  • Most Recent Events

    • 22 May 2007 Status change
    • 10 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top